CBIV's $58M Close Bets on a Trillion-Dollar Women's Health Tech Market

TORONTO, ON – August 06, 2026 – In a capital market that remains cautious, Cross-Border Impact Ventures (CBIV) has sent a clear signal of confidence, announcing a US$58 million first close for its Women’s and Children’s Health Technology Fund II. The figure, secured on the path to a US$125 million target, is more than just a number; it is a validation of a powerful investment thesis that sits at the intersection of profound social impact and immense financial opportunity.

With commitments from a roster of returning and new institutional investors, including Germany’s KfW, the Skoll Foundation, and the Equality Fund, CBIV is effectively doubling down on a sector historically marginalized by mainstream venture capital. The move underscores a growing recognition that improving health outcomes for women and children is not merely a moral imperative but a cornerstone of a multi-billion-dollar market poised for explosive growth.

Validating the Thesis: From Fund I Success to Fund II Ambition

To understand the conviction behind Fund II, one must look at the performance of its predecessor. CBIV's inaugural US$90.3 million fund was not a speculative dip into impact investing; it was a disciplined deployment of capital into 11 deep-tech companies. The portfolio spanned critical health verticals from oncology to maternal health, ultimately reaching over 356,000 women and children across 32 countries.

Crucially, the firm demonstrated its ability to generate significant financial returns alongside this impact. The strategic exit of Sonio, a French fetal ultrasound software company acquired by Samsung Medison for a reported US$92 million, provided a powerful proof point. This successful exit was not just a win for Fund I's limited partners; it was a market validator for the entire women's health technology space, proving that innovative solutions in this area can command premium valuations from major strategic acquirers.

Fund II represents what the firm calls a “disciplined evolution” of this strategy. It will continue to target early-growth-stage companies at the Series A or B stage, focusing on medical devices, diagnostics, therapeutics, and AI-enabled digital health. However, the new fund also allows for earlier-stage investments in particularly high-potential companies, providing the flexibility to nurture groundbreaking ideas from a nascent stage.

The Trillion-Dollar Opportunity in Underserved Markets

The financial logic underpinning CBIV’s strategy is compelling. The firm estimates the current market for its sectors of interest at US$625 billion, projecting it to surge to US$1.1 trillion by 2035. While ambitious, these figures are supported by a confluence of powerful market drivers and independent research.

For decades, medical research and product development have disproportionately focused on men, creating significant gaps in care for women. A recent McKinsey Health Institute report found that closing this health gap could add over US$1 trillion to the global economy annually by 2040. Investors are now waking up to the commercial potential of addressing these longstanding inequities. The growth is fueled by advances in AI, precision medicine, and diagnostics, which are enabling highly personalized and effective solutions for conditions that affect women specifically, differently, or disproportionately.

The FemTech market alone, though definitions vary, is on a steep upward trajectory. Projections from firms like Grand View Research and Precedence Research see the market expanding at a compound annual growth rate of over 15%, driven by demand for better solutions in fertility, menopause, and chronic disease management. When combined with the growing mother and child healthcare market, which some analysts project will surpass US$2 trillion by 2034, CBIV’s trillion-dollar forecast appears not just plausible, but perhaps even conservative.

A New Standard for Impact: Integrating a Climate Lens

Beyond its core health focus, Fund II introduces a notable innovation that sets a new benchmark for venture capital: an integrated climate lens. This moves beyond traditional ESG box-ticking and embeds environmental considerations directly into the investment due diligence and portfolio management process. For a health technology fund, this is a pioneering step.

In practice, this means CBIV will evaluate potential investments on criteria such as the carbon footprint of their supply chains, resource efficiency in manufacturing medical devices, and the use of sustainable materials. It also opens the door to investing in technologies that enhance the climate resilience of health systems, a critical need as environmental stressors increasingly impact public health, with women and children often bearing the heaviest burden.

This integrated approach reflects a sophisticated understanding of impact, recognizing that human health and planetary health are inextricably linked. It signals to the market that future-proof investments must account for a wider spectrum of risks and opportunities, a standard that other funds will likely be compelled to follow.

A Crowded Field or a League of Its Own?

CBIV is not alone in recognizing the FemTech and PedTech opportunity. A growing number of specialized funds, such as Amboy Street Ventures and PediaMed Ventures, have emerged to target these specific niches. However, CBIV has carved out a distinct position in this increasingly active landscape.

Its key differentiator lies in its focus on the intersection of women's and children's health, a holistic approach that acknowledges the continuum of care from mother to child. Furthermore, its “cross-border” mandate emphasizes building globally competitive companies, expanding access to world-class technologies in both developed and emerging markets. This global perspective is a core part of its DNA, distinguishing it from more regionally focused funds.

By concentrating on early-growth-stage “deep tech” companies—those with significant intellectual property in medical devices, diagnostics, and therapeutics—the firm targets a higher-value segment of the market. The addition of the climate lens further refines its unique value proposition, appealing to a class of LPs who demand both robust financial performance and comprehensive, multi-faceted impact.

The Power of the Partnership: Why LPs are Doubling Down

The quality of a fund’s investor base is often as telling as its investment strategy. The fact that prominent LPs from Fund I have returned, many reportedly increasing their commitments, speaks volumes about their confidence in CBIV’s leadership and execution. The continued participation of KfW, a German development bank, is particularly significant. As a provider of concessionary capital, KfW’s involvement helps de-risk the fund, making it more attractive to commercial investors by offering a layer of downside protection and enhancing potential returns for other LPs.

For mission-driven investors like the Skoll Foundation and the Equality Fund, CBIV offers a proven vehicle to advance their core objectives. The fund’s explicit goal of improving health outcomes for women and children aligns directly with their mandates to tackle global inequality and foster social progress. Their renewed commitment is a testament to the tangible results delivered by Fund I and a belief that CBIV is uniquely positioned to scale that impact with its second fund.

This powerful syndicate of investors validates CBIV's model, demonstrating that it is possible to build a premier venture capital firm that does not treat financial returns and social good as a zero-sum game.